Hematopoiesis News Volume 7.18 | May 10 2016

    0
    25

    Hematopoiesis News 7.18 May 10, 2016

    Hematopoiesis News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  HN on Twitter

     
    TOP STORY
    Single-Cell Transcriptional Analysis of Normal, Aberrant, and Malignant Hematopoiesis in Zebrafish
    Researchers have transcriptionally profiled single hematopoietic cells from zebrafish to define erythroid, myeloid, B, and T cell lineages. They used their approach to identify hematopoietic stem and progenitor cells and a novel NK-lysin 4+ cell type, representing a putative cytotoxic T/NK cell. [J Exp Med] Abstract
    Learn more about MegaCultâ„¢-C collagen-based medium for colony-forming unit - megakaryocyte (CFU-Mk) assays of human or mouse hematopoietic progenitor cells.

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Enhanced Thrombopoietin but Not G-CSF Receptor Stimulation Induces Self-Renewing Hematopoietic Stem Cell Divisions In Vivo
    Using in vivo high-resolution single hematopoietic stem cells (HSC) divisional tracking, investigators demonstrated that clinically applied thrombopoietin receptor but not granulocyte-colony stimulating factor receptor agonists drive HSCs into self-renewing divisions leading to quantitative expansion of functional HSC as defined by their in vivo serial multi-lineage and long-term repopulating potential. [Blood] Abstract

    Mesenchymal Stromal Cell Derived Extracellular Vesicles Rescue Radiation Damage to Murine Marrow Hematopoietic Cells
    The authors evaluated the capacity of mesenchymal stromal cells-derived extracellular vesicles to mitigate radiation injury to marrow stem cells at four hours to seven days after irradiation. [Leukemia] Abstract

    Xpg Limits the Expansion of Hematopoietic Stem and Progenitor Cells after Ionizing Radiation
    Scientists screened for genome stability factors negatively impacting maintenance of hematopoietic stem cells (HSCs) in the context of ionizing radiation (IR). They found that in vivo knock down of Xeroderma pigmentosum, complementation group G (Xpg) caused elevation of HSC numbers after IR treatment, while numbers of hematopoietic progenitors are elevated to a lesser extent. [Nucleic Acids Res] Full Article

    Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities
    To better understand functional interplay between trisomy 21 and GATA1 mutations in hematopoiesis, scientists constructed cellular disease models using human induced pluripotent stem cells (iPSCs) and genome-editing technologies. Comparative analysis of these engineered iPSCs demonstrated that trisomy 21 perturbed hematopoietic development through the enhanced production of early hematopoietic progenitors and the upregulation of mutated GATA1. [Cell Rep] Full Article | Graphical Abstract

    RNA Polymerase III Component Rpc9 Regulates Hematopoietic Stem and Progenitor Cell Maintenance in Zebrafish
    Researchers isolated a zebrafish mutant with defective T lymphopoiesis and positional cloning identified that Rpc9, a component of DNA-directed RNA polymerase III complex, is responsible for the mutant phenotype. [Development] Abstract

    Measuring ATP Concentration in a Small Number of Murine Hematopoietic Stem Cells
    Scientists showed the method of measuring the ATP levels in hematopoietic stem cells (HSCs) sorted from murine bone marrow. They used magnetic sorting as well as a cell sorter and adopted the commonly used bioluminescence-based detection kits in described protocol. Their strategy allows to measure ATP levels in 1000 highly purified HSC. [Methods Mol Biol] Abstract

    Deorphanization and Characterization of the Ectopically Expressed Olfactory Receptor OR51B5 in Myelogenous Leukemia Cells
    Scientists detected the expression of OR51B5 in the chronic myelogenous leukemia cell line K562 and in white blood cell samples of clinically diagnosed acute myelogenous leukemia patients by reverse transcription-PCR and immunocytochemical staining. [Cell Death Disc] Full Article

    CLINICAL RESEARCH

    Allogeneic Transplantation Is Not Superior to Chemotherapy in Most Patients over 40 Years of Age with Philadelphia-Negative Acute Lymphoblastic Leukemia in First Remission
    The authors retrospectively compared the outcome of patients >40 years treated with hematopoietic stem-cell transplantation (HSCT) or chemotherapy alone in first remission. Three-year overall survival and disease-free survival were not significantly different between the chemotherapy-only and HSCT groups [Am J Hematol] Abstract

    Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated with or without Fludarabine
    Researchers investigated the importance of an oral test dose for busulfan (BU) dose adjustment before conditioning regimen for hematopoietic stem cell transplantation and the effect of fludarabine on the oral BU pharmacokinetics evaluated after the 5th treatment dose. [J Clin Pharmacol] Abstract

    Cord Blood Software Like You've Never Seen It

     
    REVIEWS
    The Shelterin Complex and Hematopoiesis
    The authors introduce the biochemical features and in vivo effects of individual shelterin proteins, discuss shelterin functions in hematopoiesis, and review emerging knowledge implicating the shelterin complex in hematological disorders. [J Clin Invest] Abstract

    Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

     
    INDUSTRY NEWS
    Yissum and BioTheryX Sign Licensing Agreement for the Development of Next-Generation Protein Degradation and Immunomodulatory Treatment for Hematological Cancers
    Yissum Research Development Company of the Hebrew University of Jerusalem announced that it had signed an exclusive world-wide licensing and research agreement with BioTheryX, Inc., developer of novel protein degradation and immunomodulatory drugs for cancer and immune dysfunction, for the development and commercialization of drug candidates representing first-in-class therapy for hematologic and solid malignancies. [Yissum Research Development Company of the Hebrew University of Jerusalem] Press Release

    FDA Expands IMBRUVICA® (Ibrutinib) Label to Include New Data from Two Key Phase III Trials, Adding Overall Survival and Combination Data
    The U.S. Food and Drug Administration (FDA) has approved an expansion to the IMBRUVICA® U.S. Prescribing Information based on data supporting its use in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, Janssen announced. [Janssen Global Services, LLC] Press Release

    From our sponsor: Isolate human immune cells in as little as 8 minutes with EasySep™ Request a sample.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Worldwide Innovative Networking in Personalized Cancer Medicine (WIN) 2016
    June 27-28, 2016
    Paris, France

    Visit our events page to see a complete list of events in the hematopoiesis community.

     
    JOB OPPORTUNITIES
    NEW PhD Student – Leukemia Biology (Helmholtz Association)

    NEW Postdoctoral Fellow – Leukemia Lymphoma (Emory University)

    Scientist – Hematology (STEMCELL Technologies Inc.)

    Postdoctoral Scientist – Mouse Hematopoiesis (Lund University)

    Postdoctoral Fellow – Hematopoietic Stem Cell Biology and Blood Disorders (Brigham & Women’s Hospital)

    Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

    Postdoctoral Research Associate – Stem Cell Aging Biology (University of Southern California)

    Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

    Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

    Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Hematopoiesis News: Archives | Events | Contact Us